Semaglutide: research overview

The short version

Semaglutide is an FDA-approved GLP-1 receptor agonist — a synthetic analogue of glucagon-like peptide-1, an intestinal hormone that controls insulin secretion, glucagon release, gastric emptying, and appetite. It has multiple approved uses: type 2 diabetes, chronic weight management, cardiovascular risk reduction in people with established cardiovascular disease and obesity, and metabolic steatohepatitis (MASH, approved 2025).

Its clinical evidence base is the most extensive on this desk: the STEP 1 trial (n=1,961) showed 14.9% mean body-weight reduction over 68 weeks ^[11]; the SELECT trial (n=17,604) showed a 20% relative reduction in major adverse cardiovascular events ^[10]; the FLOW trial (n=3,533) demonstrated kidney-disease event reduction in type 2 diabetes ^[9]. This is meaningful, reproducible, large-trial human evidence — a rarer commodity than most of the peptide literature offers.

The safety profile is well documented because the trials were large enough to detect real signals. Nausea affects roughly one-third of users. Biliary disease risk is increased. Pancreatic and thyroid-cancer signals remain under surveillance without definitive conclusions ^[12].

What it is

Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two backbone substitutions make it protease-resistant: position-8 alanine is replaced by alpha-aminoisobutyric acid (Aib) to block DPP-4 cleavage, and position-34 lysine is replaced by arginine. A C18 fatty di-acid chain, attached via a spacer to the remaining lysine at position 26, drives strong albumin binding — which protects the peptide from renal clearance and is the structural basis for once-weekly dosing.

Formulations include a once-weekly subcutaneous injection and a once-daily oral tablet. The oral version uses an absorption enhancer (SNAC) and has very low bioavailability (~0.4–1%), requiring strict fasted administration to achieve effective blood levels.

How it works

Semaglutide activates GLP-1 receptors on pancreatic beta cells to potentiate glucose-dependent insulin secretion, on pancreatic alpha cells to suppress inappropriate glucagon release, and on gastric smooth muscle (via vagal afferents) to slow gastric emptying. These effects combine to lower postprandial blood glucose.

Its weight-lowering effect is primarily central: semaglutide reaches hypothalamic and brainstem appetite circuits — notably the arcuate nucleus and area postrema — where it activates anorexigenic POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons, reducing food intake. This is why people consistently report quieter 'food noise' rather than simply feeling full: the appetite-reducing effect operates on motivation, not just satiety.

GLP-1 receptors are also expressed in the cardiovascular and renal systems, which is the mechanistic basis for the pleiotropic effects observed in the SELECT and FLOW trials.

What the research shows

Weight management (STEP 1, n=1,961): Once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of −14.9% from baseline to week 68 versus −2.4% with placebo — a treatment difference of approximately 12.4 percentage points ^[11]. No earlier peptide on this desk has generated this scale of controlled weight-loss evidence.

Cardiovascular outcomes (SELECT, n=17,604): In adults with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced the primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke: HR 0.80 (95% CI 0.72–0.90; P<0.001) — a 20% relative risk reduction ^[10].

Kidney disease (FLOW, n=3,533): In type 2 diabetes with chronic kidney disease, semaglutide 1.0 mg reduced major kidney-disease events (HR 0.76; 95% CI 0.66–0.88) — a 24% lower risk versus placebo ^[9].

Head-to-head with tirzepatide (SURMOUNT-5, n=751): Tirzepatide (a dual GIP/GLP-1 agonist) produced greater mean weight loss than semaglutide at 72 weeks (−20.2% vs −13.7%; P<0.001) ^[8]. This is relevant context: semaglutide is not the ceiling of this drug class.

Safety (dedicated review): A focused safety analysis of the semaglutide clinical-trial database characterized the overall risk/benefit as favorable in type 2 diabetes; dominant adverse effects are transient GI events; biliary disease risk is increased; pancreatic and thyroid-cancer signals are monitored but without definitive conclusions; retinopathy worsening was noted in SUSTAIN-6 in patients with pre-existing retinopathy undergoing rapid glycemic correction ^[12].

Reported effects, cautions, and safety

What research-use communities report (anecdotal, not clinical evidence): The dominant reported benefit is a reduction in appetite and 'food noise' — a quieting of the constant background preoccupation with food that many describe as the most meaningful change. Reduced cravings for sweet and high-fat foods, steady weight loss over months, and improved blood-sugar readings (in people with type 2 diabetes) are frequently described. A recurring secondary observation is reduced desire for alcohol, though this is not an approved indication and the mechanism is not established. Adverse effects reported prominently in community accounts include nausea (especially early and after dose escalation), sulfur-smelling burps, bowel changes (both constipation and diarrhea), acid reflux, and fatigue on injection days.

Clinically documented cautions: A boxed warning covers personal or family history of medullary thyroid carcinoma or MEN-2 based on rodent C-cell tumor data; the human signal remains unconfirmed ^[12]. Acute pancreatitis is a class warning. Biliary disease (cholelithiasis) risk is elevated, attributed largely to rapid weight-loss rate ^[12]. Pre-existing diabetic retinopathy with rapid glycemic correction warrants monitoring ^[12]. Meaningful lean-mass loss accompanies fat-mass loss, raising sarcopenia considerations particularly in older adults. Weight regain after discontinuation is substantial and consistent across trials — an important framing for this as a chronic rather than curative intervention.

Compounded semaglutide note: During a prior federally declared shortage, compounded versions circulated; the FDA documented dosing errors and adverse events requiring hospitalization from such sources. The compounding context closed as the shortage resolved in 2025.

This page does not provide a dosing recommendation. Doses described above are reported as study-design parameters, attributed to their trials.

Where it fits on this desk

Semaglutide's place on this desk is straightforward: it has the most human trial evidence, the most clearly characterized adverse effects, and the most clearly established benefit-risk profile of the four. That does not mean everyone for whom it might be relevant should use it — it is a prescription drug — but it does mean the question 'what does the evidence actually show?' has a more complete answer here than for most peptides. The desk covers it not as a recommendation but as an illustration of what a peptide research record looks like when it has been properly run.